Literature DB >> 33061213

Transplantation for chemotherapy-induced cardiomyopathy-case series and review of current practice.

Komarakshi Rajagopalan Balakrishnan1, Kemundel Genny Suresh Rao2, Ganapathy Subramaniam3, Dhruva Sharma4.   

Abstract

Multimodality therapies have improved the survival after tumors like Ewing's sarcoma and breast cancer. However, cardiotoxicity following chemotherapy remains an important concern. We report a case series of four patients who presented to our heart team with severe dilated cardiomyopathy along with biventricular involvement. Two of the patients were females and had breast cancer for which they were treated with trastuzumab and had developed chemotherapy induced cardiomyopathy (CCMP). The other two patients were males who had Ewing's sarcoma who developed CCMP following treatment with doxorubicin. © Indian Association of Cardiovascular-Thoracic Surgeons 2020.

Entities:  

Keywords:  Cardiac transplantation; Dilated cardiomyopathy; Doxorubicin; Trastuzumab

Year:  2020        PMID: 33061213      PMCID: PMC7538490          DOI: 10.1007/s12055-020-01018-8

Source DB:  PubMed          Journal:  Indian J Thorac Cardiovasc Surg        ISSN: 0970-9134


  42 in total

1.  Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes.

Authors:  Steven E Lipshultz; Tracie L Miller; Rebecca E Scully; Stuart R Lipsitz; Nader Rifai; Lewis B Silverman; Steven D Colan; Donna S Neuberg; Suzanne E Dahlberg; Jacqueline M Henkel; Barbara L Asselin; Uma H Athale; Luis A Clavell; Caroline Laverdière; Bruno Michon; Marshall A Schorin; Stephen E Sallan
Journal:  J Clin Oncol       Date:  2012-02-27       Impact factor: 44.544

Review 2.  Chemotherapy-related Cardiomyopathy.

Authors:  Susan E Piper; Theresa A McDonagh
Journal:  Eur Cardiol       Date:  2015-07

3.  Bortezomib or high-dose dexamethasone for relapsed multiple myeloma.

Authors:  Paul G Richardson; Pieter Sonneveld; Michael W Schuster; David Irwin; Edward A Stadtmauer; Thierry Facon; Jean-Luc Harousseau; Dina Ben-Yehuda; Sagar Lonial; Hartmut Goldschmidt; Donna Reece; Jesus F San-Miguel; Joan Bladé; Mario Boccadoro; Jamie Cavenagh; William S Dalton; Anthony L Boral; Dixie L Esseltine; Jane B Porter; David Schenkein; Kenneth C Anderson
Journal:  N Engl J Med       Date:  2005-06-16       Impact factor: 91.245

4.  Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin.

Authors:  E H Herman; J Zhang; S E Lipshultz; N Rifai; D Chadwick; K Takeda; Z X Yu; V J Ferrans
Journal:  J Clin Oncol       Date:  1999-07       Impact factor: 44.544

5.  Late effects of chemotherapy and radiotherapy in osteosarcoma and Ewing sarcoma patients: the Italian Sarcoma Group Experience (1983-2006).

Authors:  Alessandra Longhi; Stefano Ferrari; Angela Tamburini; Roberto Luksch; Franca Fagioli; Gaetano Bacci; Cristina Ferrari
Journal:  Cancer       Date:  2012-03-13       Impact factor: 6.860

Review 6.  Protecting against anthracycline-induced myocardial damage: a review of the most promising strategies.

Authors:  Karlijn A Wouters; Leontien C M Kremer; Tracie L Miller; Eugene H Herman; Steven E Lipshultz
Journal:  Br J Haematol       Date:  2005-12       Impact factor: 6.998

7.  Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.

Authors:  Michel Marty; Francesco Cognetti; Dominique Maraninchi; Ray Snyder; Louis Mauriac; Michèle Tubiana-Hulin; Stephen Chan; David Grimes; Antonio Antón; Ana Lluch; John Kennedy; Kenneth O'Byrne; PierFranco Conte; Michael Green; Carol Ward; Karen Mayne; Jean-Marc Extra
Journal:  J Clin Oncol       Date:  2005-05-23       Impact factor: 44.544

8.  VAD as bridge to recovery in anthracycline-induced cardiomyopathy and HHV6 myocarditis.

Authors:  Anna Cavigelli-Brunner; Martin Schweiger; Walter Knirsch; Brian Stiasny; Karin Klingel; Oliver Kretschmar; Michael Hübler
Journal:  Pediatrics       Date:  2014-08-04       Impact factor: 7.124

9.  Identification of the molecular basis of doxorubicin-induced cardiotoxicity.

Authors:  Sui Zhang; Xiaobing Liu; Tasneem Bawa-Khalfe; Long-Sheng Lu; Yi Lisa Lyu; Leroy F Liu; Edward T H Yeh
Journal:  Nat Med       Date:  2012-10-28       Impact factor: 53.440

Review 10.  Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management.

Authors:  Edward T H Yeh; Courtney L Bickford
Journal:  J Am Coll Cardiol       Date:  2009-06-16       Impact factor: 24.094

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.